Distinguishing bacterial from viral respiratory infections drives appropriate treatment, reduces avoidable antibiotic use, and limits antimicrobial resistance. No single test is perfectly definitive; clinical assessment combined with targeted biomarkers gives the best accuracy.
Biomarkers in clinical use
Procalcitonin is the most widely studied blood biomarker for this purpose. Philipp Schuetz at Kantonsspital Aarau led randomized trials showing that procalcitonin-guided algorithms can safely reduce antibiotic exposure in lower respiratory tract infections, supporting its use as an aid to decision making. C-reactive protein is simpler and cheaper; Paul Little at University of Southampton has evaluated point-of-care CRP testing in primary care and demonstrated reductions in antibiotic prescribing when clinicians integrate CRP with clinical assessment. White blood cell count and neutrophil predominance remain routine components of assessment: marked neutrophilia favors bacterial causes while relative lymphocytosis is more typical of viral infections, but these signals are non-specific and influenced by comorbidities and timing of illness. Direct pathogen detection by molecular tests such as respiratory viral PCR provides definitive evidence of viral infection when positive and is endorsed by public health laboratories including the Centers for Disease Control and Prevention for diagnosis of viral respiratory pathogens. Thresholds and interpretation must be adapted to clinical context, disease prevalence, and assay characteristics.
Emerging host-response tests and broader implications
Host gene expression classifiers, which measure patterns of host mRNA rather than the pathogen, have shown promise. Purvesh Khatri at Stanford University and Sachin Y. Tsalik at Duke University School of Medicine have published multi-cohort analyses and clinical studies indicating that host-response signatures can distinguish bacterial from viral infections with higher accuracy than single biomarkers in some settings. These approaches remain under development and often require centralized platforms or advanced point-of-care devices.
The consequences of improved discrimination are practical and cultural. In high-resource settings, better biomarker use can shorten antibiotic courses and reduce hospital stays; in resource-limited areas, access to rapid tests is uneven, and cultural expectations about antibiotics may drive overuse despite test results. Environmental and territorial factors such as seasonal viral circulation and local resistance patterns also alter test utility. Clinicians should combine biomarkers, pathogen detection, and bedside assessment to guide therapy, recognizing that evolving evidence—supported by researchers at major institutions—continues to refine which tests are most reliable in particular clinical contexts.